Amazon and National Safety Council Create First-of-its-Kind Partnership to Solve the Most Common Workplace Injury in the U.S.
10.6.2021 15:00:00 EEST | Business Wire | Press release
Today Amazon (NASDAQ:AMZN) and National Safety Council (NSC) announced a five-year partnership to invent new ways to prevent the largest category of workplace injuries in the U.S., musculoskeletal disorders (MSDs). Amazon and NSC have been working together for months on this first-of-its-kind collaboration.
“Through this partnership we’ll be able to solve problems that people face every day so they can live their fullest lives,” said Lorraine Martin, president and CEO of National Safety Council. “Going to work should be a positive, rewarding, and safe experience. We are grateful for the generous support of Amazon to help companies around the world solve this important issue while fueling our nonprofit mission to keep employees safe in the workplace.”
"As a member of Amazon’s onsite safety team, my goal is to do everything I can to keep my fellow employees healthy at work so we all go home safe to our friends and families," said Chelsea Weimer, an hourly employee at Amazon’s fulfillment center in Baltimore, MD. "Amazon has a high standard for safety; this partnership is more proof of that and I can't wait to see the work that's done to help decrease MSDs."
The partnership will aim to prevent MSDs across a variety of industries by engaging key stakeholders, conducting research, inventing new technology and processes, and scaling the results. The collaboration is made possible by Amazon’s $12 million contribution, the largest corporate contribution in the history of NSC, and will include five key components:
Advisory Council: Establishing an international advisory council to bring together safety experts, corporations, and researchers in public and private sectors. The advisory council will work together to review the most promising approaches to MSD prevention, shape the development of partnership components, and engage external parties on MSD prevention.
Pioneering Research: Conducting research utilizing next-generation artificial intelligence, natural language processing, and machine learning tools to explore current and future MSD innovations and trends. The research will be available to all industries to explore and glean insights.
Small Business and University Grants: Providing grants to small businesses, universities, and university students. These grants will fund research and innovation that help companies of all sizes achieve impact.
Innovation Challenge: Incubating and fostering innovative and practical solutions to address MSDs through Innovation Challenge competitions. These competitions will bring together experts to collaborate, iterate, and share techniques and ideas.
Industry Call to Action – The MSD Pledge: Amazon and NSC will share solutions discovered throughout the partnership to inspire change through the creation of The MSD Pledge and a call on other companies to also join the effort to:
- Track proactive indicators of injuries to ensure proper risk mitigation and implement prevention strategies based on data.
- Implement an MSD prevention program that includes educating employees and employers about injury prevention.
- Embrace and drive forward innovative solutions to prevent MSDs and share best practices with other organizations worldwide.
The partnership kicks off in June during National Safety Month and in its first year will focus on launching the advisory council, identifying research partners, analyzing existing data, and developing the grant and Innovation Challenge programs.
“Nothing is more important than the safety of our employees, and this partnership will allow us to dive deep into the best way to reduce MSDs,” said Heather MacDougall, Amazon’s vice president of worldwide workplace health and safety. “National Safety Council has a long history of advancing safe practices in the workplace, and we look forward to working alongside them as well as many other businesses, experts, and students around the world to innovate and solve for this important issue.”
The NSC collaboration is another step in Amazon’s long-term mission to be Earth’s Safest Place to Work, which includes an investment of over $300 million into safety projects in 2021, and a goal to cut its recordable incident rate by 50% by 2025. Every day, Amazon works closely with health and safety experts, conducts thousands of safety inspections inside every building, and actively seeks employee feedback on how to improve their well-being at work. To see inside Amazon’s workplace and learn more about its team and technology, sign up for a fulfillment center tour at www.amazon.com/FCtours.
National Safety Council is America’s leading nonprofit safety advocate—and has been for over 100 years. As a mission-based organization, it works to eliminate the leading causes of preventable death and injury, focusing its efforts on the workplace, roadway, and impairment. It creates a culture of safety to keep people safer not only at work, but also beyond the workplace.
To learn more about employee safety at Amazon, visit www.amazon.com/employee-safety.
To learn more about the partnership, visit www.nsc.org/amazonpartnership.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005214/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
